BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30042009)

  • 1. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
    Sundar R; Miranda S; Rodrigues DN; Chénard-Poirier M; Dolling D; Clarke M; Figueiredo I; Bertan C; Yuan W; Ferreira A; Chistova R; Boysen G; Perez DR; Tunariu N; Mateo J; Wotherspoon A; Chau I; Cunningham D; Valeri N; Carreira S; de Bono J
    Clin Colorectal Cancer; 2018 Dec; 17(4):280-284. PubMed ID: 30042009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.
    Bakkenist CJ; Lee JJ; Schmitz JC
    Clin Colorectal Cancer; 2018 Dec; 17(4):255-257. PubMed ID: 30316683
    [No Abstract]   [Full Text] [Related]  

  • 3. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
    Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
    J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
    Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
    Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
    Morris V; Overman MJ; Jiang ZQ; Garrett C; Agarwal S; Eng C; Kee B; Fogelman D; Dasari A; Wolff R; Maru D; Kopetz S
    Clin Colorectal Cancer; 2014 Sep; 13(3):164-71. PubMed ID: 25069797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
    Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
    Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
    Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
    Zhou Y; Wan G; Spizzo R; Ivan C; Mathur R; Hu X; Ye X; Lu J; Fan F; Xia L; Calin GA; Ellis LM; Lu X
    Mol Oncol; 2014 Feb; 8(1):83-92. PubMed ID: 24145123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer.
    Grabsch H; Dattani M; Barker L; Maughan N; Maude K; Hansen O; Gabbert HE; Quirke P; Mueller W
    Clin Cancer Res; 2006 Mar; 12(5):1494-500. PubMed ID: 16533773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
    Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN;
    Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):233-41. PubMed ID: 27329169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
    Takahashi S; Sakamoto Y; Denda T; Takashima A; Komatsu Y; Nakamura M; Ohori H; Yamaguchi T; Kobayashi Y; Baba H; Kotake M; Amagai K; Kondo H; Shimada K; Sato A; Yuki S; Okita A; Ouchi K; Komine K; Watanabe M; Morita S; Ishioka C
    Cancer Sci; 2021 Apr; 112(4):1567-1578. PubMed ID: 33548159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
    Garde-Noguera J; Gil-Raga M; Evgenyeva E; García JA; Llombart-Cussac A; Camps-Herrero C
    Clin Transl Oncol; 2016 Apr; 18(4):405-12. PubMed ID: 26307753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
    Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
    Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability.
    Kim HS; Choi SI; Min HL; Kim MA; Kim WH
    PLoS One; 2013; 8(12):e82769. PubMed ID: 24324828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.
    Beggs AD; Domingo E; McGregor M; Presz M; Johnstone E; Midgley R; Kerr D; Oukrif D; Novelli M; Abulafi M; Hodgson SV; Fadhil W; Ilyas M; Tomlinson IP
    Oncotarget; 2012 Nov; 3(11):1348-55. PubMed ID: 23154512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.